NewEdge Wealth LLC Has $1.73 Million Stock Holdings in GSK plc (NYSE:GSK)

NewEdge Wealth LLC increased its stake in shares of GSK plc (NYSE:GSK) by 23.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 51,010 shares of the pharmaceutical company’s stock after buying an additional 9,613 shares during the period. NewEdge Wealth LLC’s holdings in GSK were worth $1,725,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of GSK. Indiana Trust & Investment Management Co increased its stake in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new position in GSK in the 4th quarter valued at $26,000. ST Germain D J Co. Inc. increased its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. lifted its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of GSK during the fourth quarter worth $32,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GSK. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

NYSE GSK opened at $37.59 on Friday. The firm’s 50 day simple moving average is $34.99 and its 200 day simple moving average is $37.26. The firm has a market capitalization of $77.90 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 1.12 and a beta of 0.64. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, research analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.18%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.